 |
|
Dear Reader :
This month’s edition of Citeline’s newsletter, developed in alliance with the IPA, underscores the growing might of Indian firms, as more frontline players move up our annual Generics Bulletin Top 50 ranking of the world’s leading generics and biosimilars companies. We now have four leading Indian firms in the top 10 rankings – no mean feat given the fierce competition and challenges industry has witnessed. We also bring you a piece on Fresenius Kabi’s pathway to emerge as a “first-class” biosimilar supplier worldwide, plus an important story on an all-female study of coronary interventions.
Anju Ghangurde - Executive Editor (Asia Pacific), Scrip/Pink Sheet
Dr. Shridhar Narayanan - Senior Technical Advisor - Innovation, IPA
|
|
|
|
Perspective From Industry Leaders |
|
|
|
|
Licensing & Collaboration Agreements |
|
|
|
|
|
|
|
|
|
|
|
